Drug Trial Radar · NCT05950945
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Dec 30, 2023
Primary completion
Oct 1, 2027
Study completion Oct 1, 2027
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- Jul 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative and HR-positive) unresectable and/or metastatic breast cancer.
Conditions
- Breast Cancer
Interventions
Trastuzumab DeruxtecanDrug
Intravenous administration, 5.4 mg/kg on Day 1 of each 21-day cycle until radiographic disease progression as assessed by the investigator, unacceptable toxicity, other discontinuation criteria are met, or 2 years after first dose of study drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time From the Start of T-DXd to Initiation of Subsequent Anticancer Treatment (TTNT)Time frame: Until subsequent therapy or death, assessed up to 24 months
Locations
88 sites in 10 countries. Site status is shown where the registry gives one.
Mount Sinai Medical Center
Miami Beach, Florida · Terminated
USF College of Medicine
Tampa, Florida · Withdrawn
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Beth Israel Lahey Health
Burlington, Massachusetts · Withdrawn
Overlook Medical Center
Summit, New Jersey · Recruiting
GenesisCare St Andrews Hospital
Adelaide, Australia · Terminated
Fiona Stanley Hospital
Murdoch, Australia · Withdrawn
Mater Hospital Sydney
North Sydney, New South Wales, Australia · Terminated
Monash Medical Centre Moorabbin
East Bentleigh, Victoria, Australia · Terminated
Institut Jules Bordet
Anderlecht, Belgium · Recruiting
GZA Ziekenhuizen
Antwerp, Belgium · Withdrawn
Universitair Ziekenhuis Brussel
Brussels, Belgium · Withdrawn
Cliniques Universitaires Saint-Luc
Brussels, Belgium · Withdrawn
UZ Leuven
Leuven, Belgium · Withdrawn
Centre Hospitalier Universitaire de Liege Sart-Tilman
Liège, Belgium · Withdrawn
GZA Ziekenhuizen
Wilrijk, Belgium · Recruiting
Centro de Oncologia - Unidade Brasília - Hospital Sírio Libanês
Brasília, Brazil · Recruiting
CIONC-Centro Integrado de Oncologia de Curitiba
Curitiba, Brazil · Recruiting
Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer
Curitiba, Brazil · Recruiting
CEPON - Centro de Pesquisas Oncológicas de Santa Catarina
Florianópolis, Brazil · Recruiting
Oncosite - Centro de Pesquisa Clinica e Oncologia
Ijuí, Brazil · Recruiting
Fundação Doutor Amaral Carvalho
Jaú, Brazil · Recruiting
Instituto de Cancer de Londrina
Londrina, Brazil · Recruiting
Hospital das Clínicas FMRP-USP
Riberão Preto, Brazil · Recruiting
Hospital Nossa Senhora da Conceicao
Rio Grande, Brazil · Recruiting
Ensino e Terapia de Inovação Clínica AMO-ETICA
Salvador, Brazil · Recruiting
Catarina Pesquisa Clinica
Santa Catarina, Brazil · Recruiting
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
Santo André, Brazil · Recruiting
Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto
São José do Rio Preto, Brazil · Recruiting
ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira
São Paulo, Brazil · Recruiting
Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda
São Paulo, Brazil · Recruiting
Beijing Hospital
Beijing, China · Recruiting
307 Hospital of PLA
Beijing, China · Recruiting
Fujian Cancer Hospital
Fujian, China · Recruiting
Sun Yat sen University Cancer Center
Guangzhou, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, China · Recruiting
Anhui Provincial Cancer Hospital
Hefei, China · Recruiting
Shandong Cancer Hospital
Jinan, China · Recruiting
Yunnan Cancer Hospital
Kunming, China · Withdrawn
Nanchang People's Hospital
Nanchang, China · Recruiting
Showing 40 of 88 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.